We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LTB Infection Estimated with Interferon-γ Release Assay

By LabMedica International staff writers
Posted on 01 Nov 2018
Image: The T-SPOT.TB test is a unique, single-visit blood test for tuberculosis (TB) screening, also known as an interferon gamma release assay (IGRA) (Photo courtesy of Oxford Immunotec).
Image: The T-SPOT.TB test is a unique, single-visit blood test for tuberculosis (TB) screening, also known as an interferon gamma release assay (IGRA) (Photo courtesy of Oxford Immunotec).
Latent tuberculosis (LTB), also called latent tuberculosis infection (LTBI) is when a person is infected with Mycobacterium tuberculosis, but do not have active tuberculosis. Active tuberculosis can be contagious while latent tuberculosis is not, and it is therefore not possible to get infected from someone with latent tuberculosis.

In Japan, university students, including foreign-born students, undergo TB screening with chest radiograph; however, a chest radiograph cannot detect LTBI; it detects only pulmonary TB. Because immigrants may develop TB after entry, screening with chest radiograph might be ineffective; therefore, screening for LTBI may be necessary to prevent TB outbreaks.

Scientists at Keio University School of Medicine (Tokyo, Japan) and their colleagues enrolled 177 participants 20–42 years of age (median 23 years), of whom 98 (55.1%) were female. Participants were from China (55 students), Indonesia (24 students), France (19 students), Germany (nine students), and Thailand (eight students); the remaining participants were from 28 different countries; including 50 from countries with estimated TB incidence rates greater than 100 cases/100,000 persons.

The team collected whole blood specimens for the T-SPOT.TB test, an Interferon-γ Release Assay (IGRA) available in Japan. All participants were screened for pulmonary TB with chest radiograph. They interviewed participants using a structured questionnaire on identification and demographic information, the date of first arrival in Japan, and history of TB.

The scientists found that overall, eight (4.5%) students tested positive on IGRA (two each from China and Thailand and one each from Ghana, Indonesia, South Korea, and the Philippines). The rate of the positive IGRA result for students from countries with an estimated TB incidence rate of >100 cases/100,000 persons was 10.0% and relative risk was 4.2, whereas the rate for students from countries with an estimated TB incidence rate of <100 cases/100,000 persons was 2.4%. The IGRA positivity of students 20–29 years of age from countries with estimated TB incidence rates of >100 cases/100,000 persons was 9.4%.

The authors concluded that estimated LTBI rates for foreign-born students in Japan from countries with high TB incidence rates were higher than those for students from countries with low TB incidence rates and for students from Japan. Based on their findings, they recommend that universities screen for LTBI using IGRAs in students from countries with high TB incidence rates (i.e., >100 cases/100,000 persons). The study was published in the November 2018 issue of the journal Emerging Infectious Diseases.

Related Links:
Keio University School of Medicine

New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Specimen Radiography System
TrueView 200 Pro

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Researchers have developed the first ever test for early detection of multiple sclerosis (Photo courtesy of 123RF)

Blood Test Detects Multiple Sclerosis Risk Years Before Onset of Symptoms

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that affects around 2.8 million people worldwide. Its development is linked to immunological processes triggered... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL